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Accelerated partial breast irradiation (APBI) is 
an alternative protocol to whole breast irradiation 
(WBI) in which treatment is performed only in 
a restricted area of breast tissue surrounding the 
tumor bed. APBI delivers a higher dose of radiation 
to a smaller breast tissue consisting of the lumpec-
tomy bed and a margin during a short period of 
time (few days versus several weeks in WBRT) [1, 
AbstrAct
background: angiosarcoma may rarely complicate radiotherapy of breast cancer. this so-called radiation-induced angiosar-
coma (rIas) occurs in less than 0.3% of patients that underwent breast conservation surgeries, usually years after completion 
of radiotherapy. 
case presentation: we introduce two cases of invasive ductal carcinoma who underwent lumpectomy and accelerated partial 
breast irradiation (apBI) as an alternative protocol to whole breast irradiation (WBI). they received adjuvant partial breast ra-
diotherapy on tumor cavity for a total dose of 38.5 Gy in 10 fractions in 5 days using 3D-external-beam rt. In both cases, rIas 
occurred eight years after radiotherapy, in the sub-cicatricial area in one patient and outside the irradiated area in the other 
one. they both underwent radical surgery and chemotherapy was performed in one patient.
Discussion: the underlying mechanism for development of rIas is not well known, but its incidence seems to be increasing. 
rIas after partial breast irradiation is very rare and has been reported in two cases so far. as it may be suggested in case 2, it is 
still a matter of debate if the risk of radiation-induced sarcoma is radiation-dose dependent. although mastectomy is consid-
ered as a standard treatment, choice of treatment should be made according to the patient’s specifications.
conclusion: there are very few studies in the literature that report rIas after apBI. present study is the only one reporting two 
cases after the external 3D technique apBI. prognosis of rIas remains poor. only a careful evaluation in a multidisciplinary 
context can offer to the patients the best result in terms of local control and survival.
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2]. Several studies report a non-inferiority of APBI 
compared to WBRT in terms of local control and 
overall survival [3,4] and the use of this technique 
is gaining more and more importance in clinical 
practice. 
Radiotherapy for breast cancer may be com-
plicated by radiation-induced angiosarcoma 
(RIAS). RIAS is a late toxicity that occurs in 0.05 
to 0.3% of patients of breast cancer who under-
went breast-conserving-surgery and adjuvant ra-
diotherapy. It seems that its incidence has been 
increasing in recent years mirroring the increasing 
use of adjuvant radiation after breast conserving 
surgery (BCS) and its long latency time [5]. Despite 
its rarity, RIAS is usually described to occur nearly 
10 years after breast irradiation. However, time in-
tervals between 6 months up to 23 years have been 
reported in literature [6, 7]. A recent review of Sur-
veillance, Epidemiology, and End Results (SEER) 
data showed a 9-fold increased risk of breast and 
chest wall RIAS after breast cancer irradiation [8]. 
Treatment of RIAS is a matter of controversy. Sur-
gery is considered the standard of treatment and 
may consist in tumor resection or mastectomy [8]. 
A population-based study performed in 2019 re-
ported that an overall survival benefit of adding 
radiotherapy to surgery could not be confirmed [9].
Due to its rarity, information about physiopatho-
logical or radiobiological mechanisms underlying 
the development of RIAS are still lacking, with sub-
sequent absence of clear, international recommen-
dations on management and/or prevention.
We reported our experience of multidisciplinary 
management of two cases of RIAS secondary to 




F.C: Seventy-one-year-old woman with histo-
logically confirmed invasive, ductal carcinoma of 
the right breast, grade 2, who underwent central 
lumpectomy and sentinel lymph nodes dissection, 
Luminal A cancer, pT1cNmic, negative surgical 
margins (R0), M0. Then, she received adjuvant 
partial breast radiotherapy of the tumor cavity for 
a total dose of 38.5 Gy in 10 fractions (3.85 Gy, 
twice daily, with daily interfractions time interval 
of at least 6 hours), target volume delineated as 
the site of lumpectomy plus the surrounding tis-
sue. Adjuvant hormonal therapy with Aromatase 
inhibitor was also prescribed for five years. At the 
end of radiotherapy, the patient started regular fol-
low up at our Breast Unit. Annual mammography 
and complete clinical examination every 6 months 
were performed for the first two years, annually 
thereafter, with no clinical or radiologic evidence 
of disease recurrence occurring in the next years.
Eight years after APBI, a sub-cicatricial lump was 
identified. A subsequent ultrasound (US) examina-
tion, identified a 40 mm nodule beyond the nipple. 
Trucut biopsy confirmed histological diagnosis of 
angiosarcoma. No pathological lymph-nodes or 
metastasis were found at CT-scan and PET-CT 
restaging. Finally, ipsilateral mastectomy was per-
formed after patient’s interview with a collegial, 
careful evaluation of risks and benefits, surgical and 
oncological outcomes deriving from a aggressive 
versus conservative therapeutic approach. Patho-
logical specimen reported a 6-cm-large cutaneous 
breast angiosarcoma, with negative surgical mar-
gins.  In view of the complete surgical excision 
of the lesion, taking into account the histological 
characterization, the previous treatments and pa-
tient’s older age, adjuvant treatment has not been 
proposed. Actually patient is pending follow up 
PET TC scan restaging.
case 2
B.M.P: Sixty-nine-year-old woman after upper 
external lumpectomy and sentinel lymph node bi-
opsy for the right breast, grade 2, invasive duc-
tal carcinoma, Luminal A cancer, pT1bN0M0R0. 
Adjuvant partial breast radiotherapy of the tumor 
cavity, with a total target dose of 38.5 Gy in 10 
twice-daily fractions (3.85 Gy/fraction, a minimum 
of 6 hours between daily fractions). Adjuvant hor-
monal therapy with Aromatase inhibitor for five 
years was also prescribed.
At the end of the radiation treatment, the pa-
tients started a regular follow up at our Breast Unit. 
Annual mammography plus Breast US and com-
plete clinical examination every 6 months were per-
formed for the first two years, annually thereafter. 
No clinical or radiologic evidence of disease recur-
rence was evident during follow up. Eight years after 
the end of partial radiotherapy treatment, when the 
patient was 77 years old, solid skin lesions quickly 
appeared in the inner quadrants of the right, resid-
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ual breast. There was evidence of widespread skin 
thickening at the subsequent mammography, with 
the presence of multiple, solid, cutaneous and sub-
cutaneous nodules. Fine needle aspiration biopsy 
confirmed histological diagnosis of angiosarcoma. 
Such breast tumor masses grew quickly after the 
onset until they also reached the ipsilateral, outer 
quadrants. All this considered, following multi-
disciplinary discussion of the case at our Institu-
tional Breast Tumor Board, right mastectomy was 
performed. The final histological exam reported 
a Grade 3, multifocal angiosarcoma involving the 
skin and residual post-lumpectpmy mammary 
parenchyma. Docetaxel and gemcitabine were ad-
ministered as a systemic treatment because of car-
diological comorbidities in which the use of anthra-
cyclines is contraindicated. Unfortunately, systemic 
treatment was stopped after the first two cycles for 
Grade 3 gastrointestinal toxicity. Six months after 
surgery, the patient developed multiple pulmonary 
and pleural metastases and massive pleural effusion 
that resulted in her death one year later surgery.
radiotherapy characteristics
In all treatments, including both cases, 3D ex-
ternal beam radiation was the technique used to 
perform APBI, according to the internal study pro-
tocol. The recommended technique consists of 4 
fields: 2 tangential coplanar and two non-coplanar 
high-energy X photons (6 MV), with possible ho-
mogenization of the dose distribution by wedge 
filters. At least 90% of the PTV was to receive > 90% 
of the prescribed dose. The following OARs dose 
constrains were considered: 1) the limiting dose to 
the skin should not exceed 90% of the prescribed 
dose (PD), 2) ipsilateral breast: <60% breast should 
receive > 50% of the PD and <35% of the breast 
should receive 100%; 3) ≤ 3% of the PD to the entire 
volume of the contralateral breast; 4) > 30% of the 
PD administered to < 15% of the ipsilateral lung; 
5) > 5% of the PD to < 5% of cardiac volume for 
right breast lesions; 6) > 5% of the PD at <40% of 
cardiac volume in left breast lesions.
Discussion
The association between ionizing radiation (IR) 
exposure and second malignancies has been well 
demonstrated in epidemiologic studies [10]. In 
particular, RIAS may be a rare but aggressive, late, 
secondary effect of breast radiotherapy . RIAS has 
been more frequently found in older women with 
a history of breast conservation surgery and radia-
tion therapy since breast carcinoma commonly oc-
curs in women between the ages of 55 and 69 [11].
Several mechanisms have been proposed to explain 
the physiopathological mechanisms underlying the 
development of RIAS. First, photons directly affect 
the DNA structure by inducing DNA breaks, par-
ticularly double-strand breaks. Secondary effects 
are the generation of reactive oxygen species (ROS) 
that oxidize proteins and lipids, but also induce ad-
ditional damages to DNA, like generation of abasic 
sites and single strand breaks. All these findings may 
be responsible for genomic instability and cancer‐
related genes mutation. About RIAS, several gene 
mutations have been reported in literature, some 
of which may be used to distinguish radiation‐in-
duced sarcomas from sporadic ones. Among these: 
the inactivation of the tumor suppressor gene p53, 
and the amplification of the 8q24 region containing 
the myc oncogene. Noteworthy, the prolonged cel-
lular irritation ischemic breast and axillary tissues 
damaged by radiation-induced chronic lymphede-
ma may interfere with the repair mechanisms, and 
promote tumorigenesis by increasing the amount 
of vascular growth factors within the tumor micro-
environment. In this regard, FLT4 gene amplifica-
tion (encoding VEGFR3) and KDR gene mutation 
(encoding VEGFR2) have been described to have 
a possible role in the development of RIAS. Fi-
nally, an association between breast cancer‐related 
tumor-suppressor genes BRCA1/BRCA2 and RIAS 
may also exist, although the exact mechanism has 
yet to be established [12–15]. Histologically, RIAS 
usually presents with irregular, anastomosing ves-
sels, lined by crowded swollen endothelial cells, 
with a scarce cytoplasm, showing different degrees 
of nuclear atypia. Typical immunohistochemical 
markers include CD31, CD34, factor VIII‐related 
antigen, FLI1, ERG, and ulex europaeus 1 lectin 
[16–18]. RIAS has been reported to originate from 
the skin above the breast target volume, inside 
the radiation field. However, in some cases it may 
develop within the mammary parenchyma, aris-
ing from parenchymal vascular endothelial cells 
[19–22]. In our experience, 2 (0.67%) patients de-
veloped RIAS after adjuvant APBI for early breast 
cancer out of 296 patients recruited as part of an 
Italian, multicenter, randomized, prospective trial 
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(I.R.M.A Trial — NCT01803958) about efficacy 
and safety of APBI in early breast cancer treatment.
Patient 1 developed pericicatricial angiosarcoma 
originated from the skin inside the irradiation field, 
without evidence of mammary parenchymal in-
volvement. In the second case, angiosarcoma de-
veloped far from the high-dose radiation site (that 
is, the tumor bed), in the lower quadrants, then it 
rapidly spread to all quadrants and finally involved 
the above skin and the entire, post-BSC, residual 
mammary parenchyma. In both cases, APBI was 
performed using a conformal, external beam radia-
tion technique (3D-CRT), with 4 fields and 6 MV 
photon beams (Fig. 1). The maximum dose to the 
whole residual breast volume was 40 Gy for Patient 
1 and 40.3 Gy for Patient 2. In the second case, in 
the region in which angiosarcoma occurred, the 
average and maximum dose were 34 Gy and 39 
Gy, respectively, and the volume corresponding to 
recurrence angiosarcoma was covered by 30% iso-
dose (11.6 Gy). Indeed, it is still a matter of debate if 
the risk of RIAS is truly radiation-dose dependent.
To our knowledge, there are only two reported 
cases of RIAS after APBI, both as a consequence of 
treatment with MammoSite balloon Brachytherapy 
[23, 24]. Mansfield et al. [24] reported a case of 
a 75-year-old woman who developed RIAS with 
skeletal muscle invasion, in association with inva-
sive ductal carcinoma, 8 years after partial breast 
treatment with MammoSite brachytherapy. RIAS 
originated close to the MammoSite applicator. Fur-
thermore, the authors reported that an adjuvant 
radiotherapy of the chest wall was performed after 
mastectomy. Long-term survival data are not re-
ported. 
Andrews et al. [23] described a case of RIAS that 
occurred 74 months after MammoSite brachyther-
apy. Similarly, RIAS occurred close to the applicator 
field. In both cases, the administered dose was 34 
Gy in twice-daily 10 fractions. Table 1 summarizes 
the main characteristics of the cases.
The latency for development of breast RIAS 
seems to be shorter when compared to radiation‐
induced sarcomas in general, with a reported aver-
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Figure 1. external beam radiation planning treatment for accelerated partial breast irradiation. A. patient 1; b. patient 2
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age of 10 to 12 years to develop after irradiation [25, 
26]. It should be noted that in our patients and the 
case presented by Mansfield, RIAS occurred exactly 
eight years after radiotherapy treatment. 
Due to its rarity, there are few scientific evidence 
regarding the management of RIAS. Mastectomy 
with negative margins is considered the standard 
of care. Negative margins are thought to be more 
important than the type of surgery itself for local 
control [27]. 
The role of chemotherapy has not been clearly 
established, and it is still object for study. Most 
of the available data originated from retrospective 
series or few case reports, and suggested that an-
giosarcomas are relatively sensitive to taxanes and 
anthracyclines [28]. 
The role of radiotherapy is controversial, instead, 
given the role of radiation in the pathogenesis of 
RIAS. Albeit with a low level of evidence, some 
studies reported an improved local control with 
re-irradiation after radical surgery. However, the 
available literature is too scarce to reach a conclu-
sion [29, 30].
conclusion
Radiation-induced angiosarcoma is a rare but 
aggressive type of cancer, which may occur as a sec-
ondary, late effect of breast irradiation after BSC. 
Actually, RIAS is a matter of debate, and many as-
pects about its origin and management are still to 
be better clarified or controversial. Due to its rarity, 
reports on such possible complication after APBI 
are still lacking in literature. To our knowledge, the 
present study is the first one to describe two events 
of RIAS after APBI using a 3D-CRT technique. 
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